Aquaporins, a family of water channel proteins, are essential for facilitating selective water transport across cellular membranes, thereby maintaining crucial physiological processes such as hydration, osmotic balance, and intracellular signaling. Among these, AQP3 also permits the passage of glycerol, linking it to metabolic functions and cellular energy homeostasis. Until now, the molecular underpinnings of how AQP3 modulates its permeability in response to fluctuating biochemical conditions remained largely elusive, stalling progress in targeted biomedical interventions.

Through cutting-edge cryo-electron microscopy paired with advanced molecular dynamics simulations, the investigative team led by Huang and colleagues achieved high-resolution visualization of AQP3’s structural transitions. The data revealed that changes in extracellular pH and intracellular redox status trigger conformational modifications within key residues lining the channel pore. These adjustments culminate in a gating mechanism that tightly regulates the opening and closing of AQP3, preventing indiscriminate passage of molecules under stress or altered physiological states.

The study highlights that under acidic conditions—a common feature of pathological states such as inflammation or ischemia—the extracellular domains of AQP3 undergo protonation, which facilitates structural rearrangements that occlude the channel’s conduit. Concurrently, shifts in the redox environment, often indicative of oxidative stress, result in the formation or breakage of disulfide bonds within cytoplasmic loops, reinforcing the channel closure from the intracellular side. This dual sensing and response system underscores AQP3’s ability to finely tune its activity in response to the cellular microenvironment.

These insights bear significant implications for our understanding of cellular water and solute homeostasis, especially in organs like the kidney, skin, and respiratory tract, where AQP3 expression is abundant and dynamically regulated. The researchers propose that this autoregulatory mechanism might serve as a protective adaptation, preventing excessive solute flux during metabolic disturbances or cellular damage, thereby preserving cellular integrity.

Moreover, the revelation of these molecular details paves the way for novel therapeutic approaches. Conditions such as cancer, where AQP3 is implicated in metastasis and increased cell motility, or skin diseases involving barrier dysfunction, could be targeted by modulating the channel’s gating properties. Pharmacological agents designed to stabilize AQP3 in its closed or open states might offer new avenues to control tissue hydration and cell migration more precisely.

The authors also noted the importance of the structural domains involved in gating as potential drug targets. Overlaying the structural data with known mutational analyses, the study contextualizes how specific amino acid alterations can affect channel behavior, which has direct relevance for genetic disorders linked to aquaporin malfunction. This could spearhead the development of personalized medicine strategies that address dysfunctional channel gating caused by genetic variants.

Additionally, the research underscores the remarkable evolutionary conservation of aquaporin gating mechanisms, suggesting that similar proton- and redox-dependent regulatory strategies may exist in homologous proteins across different species. Comparative structural assessments indicate that these adaptive features have been finely tuned to maintain cellular homeostasis under a broad range of environmental stressors.

The detailed structural characterization also extends previous models, which predominantly viewed aquaporin regulation as passive or reliant solely on external gating by auxiliary proteins. Instead, Huang and team’s findings advocate for an intrinsic, highly specialized self-regulatory system within AQP3, marked by dynamic interplay between extracellular and intracellular cues, highlighting a sophisticated level of molecular control.

Going forward, the use of integrative approaches combining structural biology, biochemistry, and live-cell imaging will be critical to unravel the temporal dynamics of AQP3 gating in physiologically relevant scenarios. Understanding how fast and reversible these conformational changes occur in living cells could provide deeper insights into how tissues tune water permeability in real time, especially under fluctuating metabolic demands.

Furthermore, the discovery pushes boundaries in biomedical science by linking fundamental structural biology with pathophysiological phenomena, enhancing our grasp of how water channel dysregulation contributes to disease mechanisms. The implications resonate beyond basic science, promising potential breakthroughs in diagnostics and therapeutics for a broad spectrum of conditions centered around fluid balance and cellular stress responses.

In summary, this work elucidates a novel autoregulatory gating mechanism in Aquaporin-3, driven by environmental pH and redox cues, whose structural basis was uncharted until now. This deepens our molecular understanding of aquaporin function and introduces new paradigms for regulating essential cellular processes involving water and glycerol transport.

The findings presented are a testament to the power of multidisciplinary research in decoding complex biological machinery. As the field advances, harnessing this knowledge could lead to innovative interventions in water channel-related pathologies and highlight aquaporins as promising targets for precision medicine.

Ultimately, Huang et al.’s study not only advances molecular biophysics but also enriches our conceptual framework of how cells maintain homeostasis through self-regulating molecular devices, reflecting nature’s intricate design in sustaining life at the microscopic scale.

Subject of Research: Structural mechanisms regulating Aquaporin-3 channel closure in response to pH and redox state changes.

Article Title: Structural insights into AQP3 channel closure upon pH and redox changes reveal an autoregulatory molecular mechanism.

Article References:
Huang, P., Venskutonytė, R., Wilson, C.J. et al. Structural insights into AQP3 channel closure upon pH and redox changes reveal an autoregulatory molecular mechanism. Nat Commun 16, 10997 (2025). https://doi.org/10.1038/s41467-025-67144-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-67144-2

Central to this discovery is the elucidation of the structural intricacies governing midnolin’s interaction with the 26S proteasome, the cell’s primary protein-degrading machinery. Utilizing cryo-electron microscopy (cryo-EM), researchers have resolved high-resolution structures of midnolin bound to the 26S proteasome in several functional states. These structures reveal a sophisticated ‘two-arm’ binding mode: the highly conserved α-helix at midnolin’s C-terminus anchors robustly to the RPN1 subunit, while its N-terminal ubiquitin-like domain interfaces with the RPN11 subunit of the 19S regulatory particle. Such an arrangement meticulously positions the substrate-binding Catch domain directly above the proteasome’s AAA-ATPase motor, a spatial orientation that maximizes substrate processing efficiency. This structural insight elucidates the molecular basis for midnolin’s capacity to circumvent ubiquitin tags, directly catalyzing protein degradation.

The functional characterization of midnolin-recognized degrons further positions this pathway as a versatile platform for targeted degradation. Researchers meticulously characterized these degrons—the specific motifs or domains within substrate proteins that confer midnolin recognition—and demonstrated the versatility by which midnolin mediates degradation. Importantly, midnolin can facilitate degradation by either direct recruitment of substrates or indirectly through intermediary adaptors, expanding the repertoire of targetable proteins. Given that midnolin expression is often elevated in various cancers, this property raises the compelling possibility of harnessing endogenous midnolin levels for therapeutic intervention, enabling selective degradation of pathological proteins within oncogenic contexts.

Pushing the boundaries from mechanistic understanding to application, the study presents the development of engineered midnolin-based targeting chimeras, termed MidTACs. By replacing midnolin’s native Catch domain with a customizable target-recruiting module, these chimeras redirect the degradation machinery toward user-defined substrates, operating independently of ubiquitination signals. Using a fully reconstituted in vitro system, MidTACs have been validated to promote effective proteasomal degradation of desired targets. This modular engineering overcomes critical limitations faced by existing TPD platforms, particularly where ubiquitination machinery engagement is inefficient or undesirable.

A standout application of this technology was the targeted degradation of nuclear β-catenin, a notoriously elusive oncogenic driver widely recognized as “undruggable.” Canonical β-catenin involved in adherens junctions displays essential physiological roles; however, nuclear β-catenin translocation leads to aberrant transcriptional programs in numerous cancers and fibrotic diseases. Previous therapeutic efforts have been hampered by the inability to discriminate between nuclear and cytosolic pools. The MidTAC approach succeeded in specific degradation of nuclear β-catenin without perturbing its cytosolic counterpart, thereby preserving cellular integrity while neutralizing the pathological driver. This precise subcellular targeting exemplifies the potential of MidTACs to achieve unparalleled specificity in TPD.

The implications of such a ubiquitination-independent degradation system are profound. By leveraging the natural degradative capacity of the proteasome without the necessity for ubiquitin tagging, the midnolin-proteasome axis circumvents rate-limiting steps and potential regulatory bottlenecks inherent to ubiquitin-dependent systems. This approach streamlines degradation pathways, potentially reducing off-target effects and broadening the spectrum of proteins amenable to therapeutic targeting. Moreover, the modular design of MidTACs enables rapid customization, facilitating the development of bespoke degraders tailored to challenging therapeutic targets.

From a structural biology perspective, the resolution of midnolin-proteasome complexes in distinct conformations illuminates the dynamic orchestration underpinning substrate engagement and processing. The ‘two-arm’ binding mechanism is reminiscent of a molecular clamp, stabilizing midnolin in an optimal configuration to deposit substrates onto the motor domains driving proteolysis. This spatial precision ensures that substrates, once recognized, are translocated efficiently into the proteolytic core, expediting breakdown. Furthermore, the evolutionary conservation of these interaction motifs underscores the fundamental biological significance of midnolin’s role in proteostasis.

Biochemically, understanding the degron landscape recognized by midnolin expands our comprehension of cellular protein quality control. This raises intriguing questions about midnolin’s physiological roles in different cellular contexts and how its proteasomal recruitment might be modulated under stress or pathological conditions. Since midnolin is overexpressed in several malignancies, it may contribute to cancer cell proteostasis networks, presenting vulnerabilities exploitable by MidTACs or similar biotechnological tools. Such cancer-selective targeting could revolutionize therapeutic windows, minimizing collateral damage to healthy tissues.

The engineering feat embodied in MidTAC design charts a versatile roadmap for next-generation TPD therapeutics. By fusing a customizable target-recognition domain onto midnolin’s proteasome-engaging scaffold, MidTACs offer precision-guided degradation that bypasses ubiquitination, a notorious hurdle in many disease models. This versatility is poised to catalyze rapid prototyping of degraders against challenging intracellular proteins, including transcription factors, scaffolding proteins, and other traditionally inaccessible targets that have evaded small molecule inhibition.

In addition to cancer, the MidTAC platform holds transformative potential against a range of diseases characterized by aberrant protein accumulation or dysregulated subcellular protein functions. The ability to selectively degrade proteins within discrete compartments, such as the nucleus, adds a spatial dimension to protein control not attainable by current technologies. This spatial precision mitigates risks of unintended systemic protein depletion and opens avenues for refined molecular therapies tailored to cellular microenvironments.

Taken together, this work not only uncovers a novel, ubiquitin-independent protein degradation pathway but also translates foundational structural knowledge into a versatile engineered platform for targeted degradation. The midnolin-proteasome pathway offers a compelling alternative to ubiquitin-centric approaches, with the prospect of overcoming critical therapeutic challenges and expanding the druggable proteome. As this technology matures, it promises to redefine the landscape of drug discovery and precision medicine, ushering a new era of protein-targeting therapeutics with unprecedented specificity and efficacy.

This pioneering study articulates a fundamental shift in targeted protein degradation, challenging longstanding dogma and illustrating the power of structural biology-driven engineering to unlock novel cellular mechanisms with therapeutic intent. As researchers worldwide harness this approach, the creation of ubiquitination-independent degraders may soon become a cornerstone of treatment strategies for a broad array of diseases, including cancer, neurodegeneration, and fibrotic disorders. The midnolin-based MidTAC system is poised to inject fresh momentum into a burgeoning field, inspiring innovative drug design paradigms with the potential to profoundly impact human health.

Article Title: Structure-based engineering of the midnolin-proteasome pathway for targeted protein degradation

News Publication Date: 20-Aug-2025

Web References: http://dx.doi.org/10.1093/procel/pwaf069

Image Credits: Hongyang Wang, Ying Zheng, Tiantian Wang, Xue Zhang, Peipei Wang, Chuancun Wei, Hongyue Li, Quan Wang, Lu Zhang, Xisong Ke, Wenqing Xu

Keywords: targeted protein degradation, ubiquitination-independent degradation, midnolin, proteasome, Cryo-EM, structural biology, MidTAC, β-catenin, cancer therapeutics, protein engineering, molecular chimeras, subcellular targeting